GlassScriptPhysician profile
Frederick Rozenshteyn
NPI 1609309558
$1,058.98
in general payments reported to CMS, 2019-2025
6 companies · $263 in 2025
The $263 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $218 · 2022: $169 · 2023: $253 · 2024: $157 · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $588 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $588.13 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $340.19 | 2021-2023 | Epclusa |
| Janssen Biotech, INC. | $284.75 | 2024-2025 | Stelara, Tremfya |
| Abbvie INC. | $248.71 | 2021-2025 | Skyrizi, Mavyret |
| Intercept Pharmaceuticals, INC. | $108.15 | 2021 | |
| Boston Scientific Corporation | $43.26 | 2022 | |
| Madrigal Pharmaceuticals | $33.92 | 2025 | Rezdiffra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Rozenshteyn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.